关键词: font-size:medium, ">卵巢癌；安罗替尼；紫杉醇；顺铂；血管生成

Abstract: Objective：To investigate the clinical efficacy of anrotinib combined with paclitaxel + cisplatin (TP) in the treatment of advanced ovarian cancer， and to analyze its effect on tumor markers and angiogenesis. Methods： A total of 80 patients with advanced ovarian cancer admitted to our hospital from February 2019 to February 2022 were selected as research objects and divided into control group (n=40) and study group (n=40) according to different treatment regimens. The control group was given TP chemotherapy， and the study group was given antirotinib +TP chemotherapy. The efficacy of the two groups and tumor markers [human epididymal protein 4 (HE4)， transferrin (SF)， carbohydrate antigen 125 (CA125)， carbohydrate antigen 199 (CA199)]， angiogenesis related factors [matrix metalloproteinase-2 (MMP-2)， vascular endothelial growth factor (VE) were compared before treatment， after 1 course of treatment， and after 3 courses of treatment GF)， human Ang-2]， tumor growth and metastasis related factors [heparin-binding epidermal growth factor (HB-EGF)， thymidine kinase 1 (TK1)， growth differentiation factor 15 (GDF15)]. Results： The total effective rate of the study group was 67.50% higher than that of the control group (45.00%) (P<0.05). The levels of HE4， SF， CA125， CA199， MMP-2， VEGF， Ang-2， HB-EGF， TK1 and GDF15 in the study group were lower than those in the control group after 1 course of treatment and 3 courses of treatment (P<0.05). There was no significant difference in the incidence of toxic and side effects between the two groups after 3 courses of treatment (P>0.05). Conclusion： Androtinib combined with TP chemotherapy is effective in the treatment of advanced ovarian cancer. It can inhibit the expression of tumor markers， inhibit tumor angiogenesis and promote the improvement of the disease.

Key words: font-size:medium, ">Ovarian cancer； Anrotinib； Paclitaxel； Cisplatin